Please assess the completion status of the following clinical trial:

Trial Title: Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females Or Males Over 18 Years Old~* Patients With Systemic Arterial Hypertension Grade I And II According With The European Society Of Cardiology~* Left Ventricular hypertrophy Demonstrated By Echocardiography~* Mild To Moderated hypercholesterolemia~* Willing To Participate And Sign The Informed Consent Form (ICF)~Exclusion Criteria:~* Type 1 Or 2 Diabetes Mellitus~* Familiar hypercholesterolemia~* Low Density Lipoprotein-Cholesterol (LDL-C) \> 190 mg/dl~* History Of Myocardial Infarction Or Stable Chronic Angina~* Triglycerides \>250 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valsartan 80 mg + Paravastin 40 mg (Type: ACTIVE_COMPARATOR): Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
- Valsartan 80 mg + Simvastatin 40 mg (Type: ACTIVE_COMPARATOR): Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
- Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg (Type: EXPERIMENTAL): Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
- Valsartan 80 mg (Type: ACTIVE_COMPARATOR): Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)

Based on this trial design, predict the completion outcome and termination type (if applicable).